|
**Overview**: T Regulatory Cells (Tregs) Panel**Introduction**: The T Regulatory Cells (Tregs) Panel is a diagnostic tool designed for immune function assessment using whole blood samples. In India, Treg dysregulation contributes to autoimmune diseases (SLE, RA, type 1 diabetes), transplant rejection, and cancer immune escape, with low Treg numbers/function linked to autoimmunity and high levels to immunosuppression in malignancies. High morbidity from under-testing in rural/low-SES patients with suspected immune dysregulation or post-transplant monitoring, limited flow cytometry labs, delayed immunomodulation leading to flares or rejection. Per immunology practices aligned with ICMR and Indian Society for Immunology guidelines, the test employs flow cytometry for CD4, CD25, FOXP3, CD127, CD45RA, CD45RO, and IL-10 over 3â€"5 days with high accuracy, valuable for quantifying Treg subsets (CD4+CD25+FOXP3+ as suppressive) and assessing function (IL-10 production). This diagnostic falls under immunological screening and targets patients with autoimmune flares, transplant recipients, or cancer immunotherapy candidates, addressing accurate detection to guide immunosuppressive adjustment or Treg-targeted therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise Treg profiling and reducing immune-related complications. Its whole blood-based approach ensures reliable cellular subset analysis.**Other Names**: Tregs Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Treg flow cytometry standard in immune monitoring; in India, expanding in transplant/autoimmune centers.**Purpose**: The test assesses 7 parameters including CD4 and FOXP3 to guide immune function assessment, quantify Treg subsets, inform immunomodulation.**Test Parameters**: 1. CD4, 2. CD25, 3. FOXP3, 4. CD127, 5. CD45RA, 6. CD45RO, 7. IL-10.**Pretest Condition**: No fasting required; patients should have immune dysregulation suspicion.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain cell viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve cell integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample required for flow).**Medical History**: Patients should provide details on autoimmune symptoms, transplant status.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected immune dysregulation including flares, benefits of assessment, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using flow cytometry by trained personnel to ensure sterile technique, avoid cell death, and interpret subsets within 3â€"5 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low cell viability can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Low CD4+CD25+FOXP3+ Tregs indicate autoimmunity risk; high levels suggest immunosuppression, necessitating specialist input.**Specialist Consultation**: Immunologists or rheumatologists should be consulted for management.**Additional Supporting Tests**: Functional suppression assays, cytokine profiling for confirmation.**Test Limitations**: Requires fresh blood; comprehensive approach required.**References**: Indian Journal of Immunology 2024, Immune Studies India 2023. |
